ADI-PEG 20 + temozolomide

**ADI-PEG 20 + temozolomide** is a combination therapy consisting of ADI-PEG 20, a pegylated arginine deiminase enzyme, and temozolomide, an oral alkylating agent. ADI-PEG 20 works by depleting systemic arginine, exploiting metabolic vulnerabilities in tumor cells that lack argininosuccinate synthetase 1 (ASS1) and cannot synthesize arginine. Temozolomide introduces DNA methylation damage in cancer cells, causing cytotoxicity. In glioblastoma, especially in ASS1-negative or ASS1-low cases, ADI-PEG 20 has both direct anti-tumor effects and immune modulatory properties, and in combination with temozolomide, it enhances therapeutic efficacy beyond either agent alone[2][4][8]. This combination is under clinical investigation in newly diagnosed glioblastoma multiforme (GBM), often as part of a regimen that also includes radiotherapy[2][7].

Other names

ADI-PEG 20 plus temozolomideADI-PEG20 plus temozolomideADI-PEG-20 plus temozolomide